These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

805 related items for PubMed ID: 33352494

  • 1. Luteolin suppresses androgen receptor-positive triple-negative breast cancer cell proliferation and metastasis by epigenetic regulation of MMP9 expression via the AKT/mTOR signaling pathway.
    Wu HT, Lin J, Liu YE, Chen HF, Hsu KW, Lin SH, Peng KY, Lin KJ, Hsieh CC, Chen DR.
    Phytomedicine; 2021 Jan; 81():153437. PubMed ID: 33352494
    [Abstract] [Full Text] [Related]

  • 2. Ononin inhibits triple-negative breast cancer lung metastasis by targeting the EGFR-mediated PI3K/Akt/mTOR pathway.
    Ganesan K, Xu C, Wu J, Du B, Liu Q, Sui Y, Song C, Zhang J, Tang H, Chen J.
    Sci China Life Sci; 2024 Sep; 67(9):1849-1866. PubMed ID: 38900236
    [Abstract] [Full Text] [Related]

  • 3. Selective activity of deguelin identifies therapeutic targets for androgen receptor-positive breast cancer.
    Robles AJ, Cai S, Cichewicz RH, Mooberry SL.
    Breast Cancer Res Treat; 2016 Jun; 157(3):475-88. PubMed ID: 27255535
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Calycosin inhibits triple-negative breast cancer progression through down-regulation of the novel estrogen receptor-α splice variant ER-α30-mediated PI3K/AKT signaling pathway.
    Li Y, Hu S, Chen Y, Zhang X, Gao H, Tian J, Chen J.
    Phytomedicine; 2023 Sep; 118():154924. PubMed ID: 37393829
    [Abstract] [Full Text] [Related]

  • 8. Dual Inhibition of Key Proliferation Signaling Pathways in Triple-Negative Breast Cancer Cells by a Novel Derivative of Taiwanin A.
    Kuo YH, Chiang EI, Chao CY, Rodriguez RL, Chou PY, Tsai SY, Pai MH, Tang FY.
    Mol Cancer Ther; 2017 Mar; 16(3):480-493. PubMed ID: 27956520
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review.
    Costa RLB, Han HS, Gradishar WJ.
    Breast Cancer Res Treat; 2018 Jun; 169(3):397-406. PubMed ID: 29417298
    [Abstract] [Full Text] [Related]

  • 11. Anti-EMT properties of CoQ0 attributed to PI3K/AKT/NFKB/MMP-9 signaling pathway through ROS-mediated apoptosis.
    Yang HL, Thiyagarajan V, Shen PC, Mathew DC, Lin KY, Liao JW, Hseu YC.
    J Exp Clin Cancer Res; 2019 May 08; 38(1):186. PubMed ID: 31068208
    [Abstract] [Full Text] [Related]

  • 12. Estrogen receptor beta increases sensitivity to enzalutamide in androgen receptor-positive triple-negative breast cancer.
    Anestis A, Sarantis P, Theocharis S, Zoi I, Tryfonopoulos D, Korogiannos A, Koumarianou A, Xingi E, Thomaidou D, Kontos M, Papavassiliou AG, Karamouzis MV.
    J Cancer Res Clin Oncol; 2019 May 08; 145(5):1221-1233. PubMed ID: 30805773
    [Abstract] [Full Text] [Related]

  • 13. Luteolin enhances drug chemosensitivity by downregulating the FAK/PI3K/AKT pathway in paclitaxel‑resistant esophageal squamous cell carcinoma.
    Yang Z, Liu H, Song Y, Gao N, Gao P, Hui Y, Li Y, Fan T.
    Int J Mol Med; 2024 Sep 08; 54(3):. PubMed ID: 38994756
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors.
    Lehmann BD, Bauer JA, Schafer JM, Pendleton CS, Tang L, Johnson KC, Chen X, Balko JM, Gómez H, Arteaga CL, Mills GB, Sanders ME, Pietenpol JA.
    Breast Cancer Res; 2014 Aug 08; 16(4):406. PubMed ID: 25103565
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. HER3/Akt/mTOR pathway is a key therapeutic target for the reduction of triple‑negative breast cancer metastasis via the inhibition of CXCR4 expression.
    Takeda T, Tsubaki M, Genno S, Tokunaga K, Tanaka R, Nishida S.
    Int J Mol Med; 2023 Sep 08; 52(3):. PubMed ID: 37477145
    [Abstract] [Full Text] [Related]

  • 18. Down-regulating GRP78 reverses pirarubicin resistance of triple negative breast cancer by miR-495-3p mimics and involves the p-AKT/mTOR pathway.
    Liu M, Yang J, Lv W, Wang S, Du T, Zhang K, Wu Y, Feng X.
    Biosci Rep; 2022 Jan 28; 42(1):. PubMed ID: 34935899
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Chrysin inhibits metastatic potential of human triple-negative breast cancer cells by modulating matrix metalloproteinase-10, epithelial to mesenchymal transition, and PI3K/Akt signaling pathway.
    Yang B, Huang J, Xiang T, Yin X, Luo X, Huang J, Luo F, Li H, Li H, Ren G.
    J Appl Toxicol; 2014 Jan 28; 34(1):105-12. PubMed ID: 24122885
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 41.